JP2022512901A5 - - Google Patents
Info
- Publication number
- JP2022512901A5 JP2022512901A5 JP2021523933A JP2021523933A JP2022512901A5 JP 2022512901 A5 JP2022512901 A5 JP 2022512901A5 JP 2021523933 A JP2021523933 A JP 2021523933A JP 2021523933 A JP2021523933 A JP 2021523933A JP 2022512901 A5 JP2022512901 A5 JP 2022512901A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antibody
- sequence
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756065P | 2018-11-05 | 2018-11-05 | |
| US62/756,065 | 2018-11-05 | ||
| US201962848524P | 2019-05-15 | 2019-05-15 | |
| US62/848,524 | 2019-05-15 | ||
| US201962855601P | 2019-05-31 | 2019-05-31 | |
| US62/855,601 | 2019-05-31 | ||
| PCT/US2019/059933 WO2020097127A2 (en) | 2018-11-05 | 2019-11-05 | B-cell activating cd73 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512901A JP2022512901A (ja) | 2022-02-07 |
| JP2022512901A5 true JP2022512901A5 (enExample) | 2022-11-10 |
| JP7650795B2 JP7650795B2 (ja) | 2025-03-25 |
Family
ID=70612455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523933A Active JP7650795B2 (ja) | 2018-11-05 | 2019-11-05 | Ｂ細胞を活性化するｃｄ７３抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220242963A1 (enExample) |
| EP (1) | EP3880710A4 (enExample) |
| JP (1) | JP7650795B2 (enExample) |
| KR (1) | KR20210100099A (enExample) |
| AU (1) | AU2019377454A1 (enExample) |
| CA (1) | CA3118706A1 (enExample) |
| IL (1) | IL282852A (enExample) |
| MX (1) | MX2021005248A (enExample) |
| WO (1) | WO2020097127A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| PE20221409A1 (es) | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| CA3174033A1 (en) * | 2020-04-09 | 2021-10-14 | Sang Hoon Cha | Monoclonal antibodies and antigen binding fragments thereof for suppressing cd73 immune checkpoint and uses thereof |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| TW202400242A (zh) * | 2022-03-14 | 2024-01-01 | 大陸商上海華奧泰生物藥業股份有限公司 | 抗體藥物偶聯物及其應用 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999024554A2 (en) * | 1997-11-12 | 1999-05-20 | University Of Pittsburgh | Isolation, characterization, and identification of dendritic like cells and methods of using same |
| CN114805575B (zh) * | 2015-12-09 | 2024-07-23 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| US20210107989A1 (en) * | 2017-04-04 | 2021-04-15 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
-
2019
- 2019-11-05 MX MX2021005248A patent/MX2021005248A/es unknown
- 2019-11-05 WO PCT/US2019/059933 patent/WO2020097127A2/en not_active Ceased
- 2019-11-05 CA CA3118706A patent/CA3118706A1/en active Pending
- 2019-11-05 US US17/290,961 patent/US20220242963A1/en not_active Abandoned
- 2019-11-05 AU AU2019377454A patent/AU2019377454A1/en not_active Abandoned
- 2019-11-05 KR KR1020217017020A patent/KR20210100099A/ko not_active Ceased
- 2019-11-05 EP EP19882254.6A patent/EP3880710A4/en not_active Withdrawn
- 2019-11-05 JP JP2021523933A patent/JP7650795B2/ja active Active
-
2021
- 2021-05-02 IL IL282852A patent/IL282852A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512901A5 (enExample) | ||
| JP2022081468A (ja) | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン | |
| US20230128449A1 (en) | Silicate containing compositions and methods of treatment | |
| JP2013538796A5 (enExample) | ||
| JP2007516966A5 (enExample) | ||
| JP2021501214A5 (enExample) | ||
| JP2022515480A5 (enExample) | ||
| JP2024531151A5 (enExample) | ||
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| JP2010519180A5 (enExample) | ||
| JP2009544585A5 (enExample) | ||
| JP2020523384A5 (enExample) | ||
| JP2021513077A5 (enExample) | ||
| JP2021534195A5 (enExample) | ||
| JP2022534118A5 (enExample) | ||
| Paderni et al. | Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects | |
| JP2009529915A5 (enExample) | ||
| JP2023549814A5 (enExample) | ||
| JP2009506043A5 (enExample) | ||
| Zimmerman et al. | Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) | |
| CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
| JP2021523096A5 (enExample) | ||
| JP2005538689A (ja) | ワクシニアまたは天然痘に対する治療のためのヒト抗体 | |
| WO2021182571A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| US20260102504A1 (en) | Glucose-responsive insulin complex, preparation method and use thereof |